Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5765564

COc1cccc(C(=O)c2ncc(CC(N)=O)c3cc(OC)c(OC)cc23)c1.O=C(O)C(F)(F)F

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GFPT1 Q06210 1/20 0.57
▸ DPP4 P27487 2/20 0.42
▸ MAPK13 O15264 1/20 0.42
▸ MAPK12 P53778 1/20 0.42
▸ MAPK11 Q15759 1/20 0.42
▸ MAPK14 Q16539 1/20 0.42
▸ VNN1 O95497 3/20 0.41
▸ PLA2G10 O15496 1/20 0.40
▸ PTGDR2 Q9Y5Y4 1/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ PDE10A Q9Y233 3/20 0.40
▸ APAF1 O14727 1/20 0.40
▸ NSD2 O96028 1/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ SENP8 Q96LD8 1/20 0.40
▸ SENP7 Q9BQF6 1/20 0.40
▸ SENP6 Q9GZR1 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1369897 0.94 GFPT1 (0.55) GFPT1DPP4MAPK13MAPK12MAPK11
Trifluoroacetic Acid SCHEMBL5744667 0.93 GFPT1 (0.68) GFPT1DPP4MAPK13MAPK12MAPK11
Trifluoroacetic Acid SCHEMBL6704167 0.92 GFPT1 (0.59) GFPT1DPP4MAPK13MAPK12MAPK11
SCHEMBL1368506 0.87 GFPT1 (0.56) GFPT1MAPK13MAPK12MAPK11MAPK14
SCHEMBL1367662 0.86 GFPT1 (0.66) GFPT1DPP4MAPK13MAPK12MAPK11
Trifluoroacetic Acid SCHEMBL6108469 0.85 GFPT1 (0.70) GFPT1DPP4PTGDR2
SCHEMBL6704170 0.85 GFPT1 (0.57) GFPT1DPP4MAPK13MAPK12MAPK11
Trifluoroacetic Acid SCHEMBL5745098 0.84 GFPT1 (0.66) GFPT1DPP4MAPK13MAPK12MAPK11
Trifluoroacetic Acid SCHEMBL5768365 0.83 GFPT1 (0.70) GFPT1DPP4VNN1PTGDR2PDE10A
Hydrochloric Acid SCHEMBL5745551 0.83 GFPT1 (0.56) GFPT1DPP4MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067529-B2 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors HOFFMANN-LA ROCHE INC. (US) 2006-06-27 — — US disclosed
EP-1631551-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-08 — — EP disclosed
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors BOLIN DAVID ROBERT (US) 2004-12-23 — — US disclosed
WO-2004101528-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors GFPT1, GLS2, GLS GFPT1 1/4885DPP4 134/4885MAPK13 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback